Executives from the Google X research unit met with officials from the US Food and Drug Administration (FDA), raising the prospect of a new product from the search giant that involves the use of biosensors, according to Bloomberg.

The meeting involved four Google executives including those that have done research on biosensors, including wireless-enabled contact lenses that monitor the wearer’s health.

The meeting was with FDA staff who regulate eye devices and diagnostics for heart conditions, according to the agency’s public calendar.

Google has developed its high-profile Glass eyewear, although it does not sound as if there is a direct link to that initiative.

The FDA’s public calendar also showed the Google representatives met with the head of the FDA office that reviews device applications for marketing approval, as well as the official who wrote the agency’s guidelines for apps.

The agency published its long-awaited guidance on how it intends to regulate health and wellness apps last September.

Among the Google participants was Andrew Conrad, who joined X last year. He is a former chief scientist at Laboratory Corporation of America Holdings and co-founder of its National Genetics Institute.

Also present was Brian Otis and Zenghe Liu. Otis is on secondment to Google from the University of  Washington where he is an associate professor in the electrical engineering department. His specialism is bionsensors and he holds a patent for a wireless-powered contact lens that uses a biosensor.

Otis is also the co-author of a paper on how wireless networks can monitor the glucose levels of contact lens wearers via the teardrops from their eyes.

Liu, who used to work for Abbott Laboratories, holds a patent for a device that uses bodily fluids to read levels of substances such as glucose or cholesterol.